B
lood pressure can be lowered in hypertensives-and even in elderly hypertensives 1 -without impairing cerebral blood flow (CBF) or CBF autoregulation. 2 Such treatmentinduced reversal of the cerebrovascular dysfunction associated with hypertension may have a beneficial effect on brain function. 3 Recently, a case has been made for a specific effect of blockade of the renin-angiotensin system (RAS). 4 An improvement in cerebrovascular autoregulatory dilatation could involve structural effects of blockade of the RAS 5, 6 or functional effects on vasomotion mediated by RAS activation.
The evidence of a cerebrovascular RAS was shown by applying renin on the surface of rabbit pial arterioles. This produced dilatation which was blocked by the angiotensin (Ang) I-converting enzyme (ACE) inhibitor, captopril. 7 However, the effects of RAS on cerebral vasomotion are unclear. Using specific AT 1 and AT 2 antagonists, it was reported that Ang II induces contraction of the rat anterior cerebral artery via AT 1 receptors. 8 Other reports suggested that AT 2 receptors were involved in dilatation. Several studies show that Ang II dilates small diameter microvessels such as the mesenteric 9 and cerebral. 10 Such Ang II-induced dilatation may involve endothelial factors such as prostaglandins 10 or nitric oxide. 11 Other reports, however, suggest that Ang II-induced vasodilatation occurs independently of any action on the endothelium and involves a direct smooth muscle cell dilatory action via calcium-activated potassium channels (BK Ca ). 9 Furthermore, the receptor involved is open to question. Noting that the number of cerebral AT 2 receptors and the degree of angiotensin-induced dilatation decreased with age, it was inferred that stimulation of the AT 2 receptor is linked to dilatation. 12 However, Haberl et al suggested that both AT 1 and AT 2 receptors are involved in Ang II-induced dila-tation, 13 whereas Feterik et al suggested that neither receptor subtype is involved. 11 With the above in mind, we undertook a series of experiments on the effects of the RAS on pial arteriolar vasomotion in the rat. Using Ang I and the ACE inhibitor captopril, we showed that Ang I is globally vasoconstrictor via its conversion into Ang II, and that Ang II vasoconstricts via an AT 1 receptor. When the latter is blocked vasodilatation occurs via an AT 2 receptor. This vasodilator response may be direct and endothelium-independent because it is blocked by the BK Ca channel blocker tetraethylammonium (TEA). 14 
Methods

Animals and Operative Procedures
Experiments were performed on 3 to 4 month-old male Wistar rats (Iffa-Credo, l'Arbresle, France; body weight: 415Ϯ8; nϭ32), housed at 24°C, exposed to 12 hours of light, and allowed free access to food and fluid. Experiments were performed in accordance with the guidelines of the French Ministry of Agriculture (Paris, France; permits 54 to 4 and 03575).
Animals were fitted with arterial and venous cannula under pentobarbital anesthesia as previously described. 15 
Measurement of Arteriolar Diameter
We measured the internal diameter of first-order cerebral arterioles through an open-skull preparation as previously described. 15 Arteriolar diameter was monitored through a microscope (Stemi 200-C; Carl Zeiss Jena GMBH) connected to a video system with a final magnification of 400ϫ. Images were digitized using a video frame grabber and diameter measured (Saisam; Microvision Instruments).
Experimental Protocols
A cumulative concentration-response curve was obtained (nϭ7) for Ang II (10 Ϫ12 to 3.10 Ϫ6 mol/L). We examined if Ang I (3.10 Ϫ6 mol/L) induced vasoconstriction following conversion to Ang II by using the converting enzyme inhibitor, captopril (N-
Ϫ5 mol/L 11 ; nϭ4). We then explored the mechanisms by which Ang II induced vasoconstriction in cerebral arterioles. We examined the effects of the angiotensin AT 1 
Ϫ5 mol/L 16 ), on arteriolar vasoconstriction induced by Ang II (nϭ5).
As Ang II induced vasodilatation in the presence of telmisartan (see Results), we determined the mechanisms of such Ang II-induced vasodilatation using the angiotensin AT 2 receptor antagonist,
Ϫ5 mol/L 11 ), in the presence of telmisartan (nϭ5). We also examined the effect of PD123319 on the vasoconstriction induced by Ang II (nϭ5). Because vasodilatation induced by stimulation of angiotensin AT 2 receptors may be mediated by activation of BK Ca channels, 9 we examined effects of the BK Ca channel blocker TEA (10 Ϫ4 mol/L) 15 on arteriolar vasodilatation induced by Ang II in the presence of telmisartan (nϭ5). As Ang II induced vasoconstriction in the presence of telmisartan and TEA, we repeated the experiments in presence of telmisartan and TEA plus PD123319 (10 Ϫ5 mol/L; nϭ4). In order to determine whether the effects of the various antagonists were specific to Ang II, experiments were also performed with an equipotent dose of another vasoconstrictor, 5HT (10 Ϫ9 and 10
Ϫ6
mol/L). Given the complexity of the experimental designs, issues of reversibility and tachyphyllaxis were dealt with in preliminary experiments. Repeated stimulation (every 10 minutes) with Ang II (10 Ϫ6 mol/L; nϭ4) showed no decrease in the response (1st stimulation Ϫ10.8Ϯ1.1%, 5th stimulation Ϫ13.0Ϯ1.9%; PϾ0.05); similar results were obtained with serotonin (10 Ϫ6 mol/L; nϭ4; 1st stimulation Ϫ17.2Ϯ1.8%, 5th stimulation Ϫ15.2Ϯ1.7%; PϾ0.05). Likewise, serotonin (10 Ϫ6 mol/L; nϭ4) produced similar vasoconstriction before (Ϫ15,2Ϯ0.7%) and after (Ϫ14.3Ϯ3.1%) Ang II (10 Ϫ6 mol/L). Because it was previously reported that Ang II can produce endothelium-dependent dilatation of cerebral arterioles 17, 18 and that pentobarbital may attenuate endothelium-dependent relaxation, 19, 20 in control experiments we showed that cerebral arterioles were capable of endothelium-dependent relaxation. Adenosine diphosphate, an endothelium-dependent vasodilator, 21 induced dosedependent relaxation of cerebral arterioles (11.4Ϯ2.7 and 16.8Ϯ2.1% at 10 Ϫ5 and 10 Ϫ4 respectively; PϽ0.05). Furthermore, L-nitro arginine methyl ester induced a small nonsignificant dosedependent contraction of cerebral arterioles (Ϫ0.5Ϯ2.3 and Ϫ3.2Ϯ1.6% at 10 Ϫ8 and 10 Ϫ7 respectively).
Substances Used
Ang II, serotonin, captopril, PD123319, L-nitro arginine methyl ester, and adenosine diphosphate were purchased from Sigma Chemical Company. Telmisartan was provided by Boehringer Ingelheim Pharma GmbH & Co KG. Sodium pentobarbital was purchased from Sanofi Santé Animale. KCl, MgCl 2 , CaCl 2 , NaCl, NaHCO 3 , urea, and glucose were purchased from Merck KGaA.
Statistical Analysis
Results are expressed as meansϮSE. mean. The experimental protocol was designed to use a paired t-test. The probability level chosen was PՅ0.05.
Results
Ang II induced dose-dependent constriction of cerebral arterioles with a maximum of Ϫ9.8Ϯ0.3 m at 3.10 Ϫ6 mol/L (Figure 1 ). Ang I-induced vasoconstriction was significantly attenuated by captopril, which had no significant effect on Telmisartan (10 Ϫ5 mol/L) had no effect on baseline diameter (41Ϯ2 m before and after; nϭ13) but reversed the effects of Ang II with an increase in internal diameter to a maximum of 4.7Ϯ0.6 m at 10 Ϫ6 mol/L (Figure 2 ). PD123319 (10 Ϫ5 mol/L) had no significant effect on baseline diameter (58Ϯ3 before versus 61Ϯ3 m after; nϭ5) but abolished vasodilatation after Ang II in the presence of telmisartan (Figure 3 ). PD123319 (10 Ϫ5 mol/L) significantly increased constriction induced by Ang II but had no effect on vasoconstriction induced by 5HT when perfused alone or in presence of telmisartan (Figure 3) .
The BK Ca channel blocker TEA (10 Ϫ4 mol/L) reversed the vasodilatation observed with Ang II in the presence of telmisartan ( Figure 4) . TEA had no effect on 5HT-induced vasoconstriction ( Figure 4 ). PD123319 significantly decreased vasoconstriction produced by Ang II in the presence of telmisartan plus TEA (Figure 4) . Ang I, Ang II, 5HT, captopril, telmisartan, PD123319 and TEA, when perfused in the cranial window, had no significant effect on systemic hemodynamics or blood gas parameters (results not shown), which were stable over the duration of the experiment (results not shown).
Discussion
The present study shows that Ang I in vivo is transformed into Ang II, which binds to AT 1 receptors, producing arteriolar constriction. When AT 1 receptors are blocked with telmisartan, Ang II dilates arterioles by binding to AT 2 receptors and the subsequent opening of BK Ca channels.
Our findings indicate that Ang II is globally vasoconstrictor principally via an AT 1 receptor. This is in agreement with other studies using rat brain vessels (eg, the middle cerebral artery) 22 but not with authors cited in the introduction and others who reported a globally vasodilator response 17, 18 or no effect of Ang II on baseline arteriolar diameter. 23 Ang II dilated rat arterioles via an AT 2 receptor when AT 1 receptors were blocked, thus AT 2 receptors linked to vasodilatation exist in rat pial arterioles. This is further suggested by the fact that the AT 2 antagonist, PD123319, potentiates Ang IIinduced vasoconstriction. Thus, the two receptors exist in rat pial arterioles and AT 1 -associated vasoconstriction predominates. In other segments of the cerebrovascular network, in other species, the two receptors may exist but AT 2 -mediated vasodilatation could predominate. The latter appears to involve smooth muscle cell BK Ca channels and not endothelium because TEA reverses Ang II-induced dilatation (in the presence of telmisartan). We cannot exclude the possibility that TEA is acting on other potassium channels or other types of neurohumoral transmission. However, we have shown that TEA inhibits vasodilatation induced by NS1619 (1-(2Ј-hydroxy-5Ј-trifluoromethylphenyl)-5-trifluoro-methyl-2(3H)benzimidazolone), a selective activator of BKCa chan- 
Vincent et al Ang II and Cerebral Arteriole Vasomotion 2693
nels. 15 It should also be noted that TEA had no effect on responses to 5HT. We also observed that the AT 2 receptor blocker, PD123319, reduced Ang II-induced vasoconstriction observed in presence of telmisartan and TEA, suggesting that Ang II induces vasoconstriction, at least partially, by stimulating receptor blocked by PD123319. Such Ang II type 2 receptor-mediated vasoconstriction has already been described in isolated mesenteric resistance arteries of spontaneously hypertensive rats (SHR). 24 Captopril blocked the vasoconstrictor action of Ang I suggesting the existence of a physiological cerebrovascular RAS. This action of the ACE inhibitor is paradoxical at first sight because ACE is situated on the endothelial cell surface and Ang I, a large peptide, was applied to the outside of the arteriole. We suppose that conversion of Ang I to Ang II can occur elsewhere than in endothelium as has been recently reported in femoral arteries. 25 Many authors have reported vasomotor effects of the angiotensins applied to the outside of arterioles (see Introduction). Although we and others 7 have provided evidence for the existence of a cerebrovascular RAS, captopril alone did not modify pial arteriolar diameter in spite of the presumably activated state of the RAS after pentobarbital anesthesia. 26 The explanation for this may lie in the relative lack of sensibility of rat microvasculature to ACE inhibitors (unless associated with salidiuretic treatment). 27 It has previously been reported that degradation products of angiotensin such as the hexapeptide Ang II-(3-8) 18 rather than Ang II itself produce arteriolar vasomotor effects. Our experiments neither confirm nor refute this possibility.
Finally, the existence of both AT 1 and AT 2 receptors in the cerebrovascular network may have important clinical implications. It has been previously reported by Nishimura 28 and Ito 29 that the AT 1 antagonists normalize CBF autoregulation in SHR. Several explanations have been given for this effect. In the light of our data, we propose a new explanation: AT 1 blockade will enhance compensatory AT 2 -mediated vasodilatation. This has been developed further by Fournier and others 30 who suggested that drugs which "activate" AT 2 receptors (Ang II receptors (AT 1 ) antagonists, calcium channels blockers, diuretics) have a more beneficial effect on stroke than drugs which "inhibit" AT 2 receptors (ACE inhibitors, ␤ blockers), for a given fall in blood pressure. However, this is still questionable because Ang II AT 1 blockers and ACE inhibitors are equally effective in reversing cerebral arteriolar remodeling, suggesting that this effect is directly mediated by blockade of AT 1 receptors. 5 Furthermore, hypertension is a disease of the elderly and expression of AT2 receptors may decrease with age. 12 We have recently reported that in an animal model of human essential hypertension (the SHR), there is a parallel increase in systemic pressure and the lower limit of CBF autoregulation, thus maintaining the cerebrovascular security margin. 5 When blood pressure is lowered with an AT 1 antagonist (telmisartan), the security margin is maintained. However for a similar blood pressure fall with an ACE inhibitor (ramipril) the security margin is reduced. 5, 31 This may be linked to compensatory activation of AT 2 receptormediated vasodilatation after specific AT 1 receptor blockade. 
